29.3 C
Vientiane
Friday, May 16, 2025
spot_img
Home Blog Page 2352

Comodo and Plexus Partner to Protect Enterprises from Cyber Attacks in Sri Lanka Market

Sri Lanka-based value-added distributor to provide Comodo security solutions to the South Asian market

BLOOMFIELD, US – News Direct – 29 March 2022 – Comodo Security Solutions, a leading provider of endpoint protection solutions, today announced that they have partnered with Plexus, a leading value-added distributor based in Sri Lanka, to provide Comodo’s solutions in Sri Lanka as well as other countries in the South Asian market.

Comodo’s Advanced Endpoint Protection (AEP) is the only solution that prevents 100% of ransomware and other malware before any damage is done. Because endpoints are the entry point for virtually all malware attacks, Comodo AEP utilizes a patented virtual isolation capability that isolates unknown files and code in a protective container until it is determined to be 100% safe. Comodo AEP is the only endpoint security solution that applies the Zero Trust principle of ‘Never Trust; Always Verify’.

“We welcome the opportunity to work with an established and leading value-added distributor in Sri Lanka such as Plexus,” said Ezra Correa, Vice President of International Business Development at Comodo. “We now have the opportunity to expand our business into a growing market, and to help organizations in Sri Lanka and surrounding countries to protect themselves against the latest ransomware and malware attacks.”

Plexus already represents world-class Enterprise Server Solutions, Data Management, IT services, Backup Power, Networking, and Network Security Solutions. Now, with Comodo added as their security solutions portfolio and trusted cyber advisor, Plexus can turn on a world-class security operation and position itself as a leader with the best security practice in the markets they serve.

“We are pleased to be working with Comodo and to have the opportunity to distribute their leading security solutions to the South Asian market,” said Damitha Haegoda, Director from Plexus. “With this partnership in place, Plexus can now offer a full breadth of IT security solutions to our customers.”

Comodo will be presenting this week at Plexus Inspire 2022, Plexus’ annual channel partner event.

About Plexus

Founded in 2017, Plexus offers global products and services to clients through its strong distribution network across Sri Lanka, the Maldives, and Singapore. Plexus is a state-of-the-art value-added distributor, with a mission to enhance the business operations of clients by providing high-value products and services and to act as the bridge between customers and solutions. For more information, visit .

About Comodo

Headquartered in Bloomfield, NJ, Comodo’s mission is to help customers avoid breaches with groundbreaking isolation technology that fully neutralizes ransomware, zero-day malware, and cyber-attacks that other security providers can’t do. We deliver active breach prevention with patented auto containment technology. Our Unified Endpoint integrates this technology with critical components like our highly rated advanced endpoint protection, endpoint detection and response, and endpoint management to offer a single cloud-accessible Active Breach Protection solution. Comodo’s SOC-as-aService team makes the solution a frictionless, high-security implementation. For more information, visit .

#CYBERSECURITY #ENDPOINT SECURITY #ENDPOINT PROTECTION

The issuer is solely responsible for the content of this announcement.

Chinachem Group: City’s largest Community Vaccination Centre on private land opens today, offering convenient service for hundreds of thousands

HONG KONG SAR – Media OutReach – 29 March 2022 – A new pop-up Community Vaccination Centre (CVC) commenced operations in the heart of Causeway Bay today (29 March), potentially allowing several hundred thousand more citizens to get fully vaccinated and help Hong Kong return to normal life as soon as possible. The CVC at the junction of Leighton Road and Caroline Hill Road is the largest yet set up within a private property portfolio, having been jointly offered to the Government for three months by Chinachem Group (the Group) and Hysan Development, who will later be developing a retail, commercial and community complex on the 160,000 sq ft site.

Photo-3.jpg

The Chief Executive Carrie Lam (5th from right), Secretary for the Civil Service Patrick Nip (5th from left), Executive Director and CEO of Chinachem Group Donald Choi (3rd from right), Executive Director and Chief Operating Officer of Hysan Development Ricky Lui (4th from left), Chief Executive of Gammon Construction Kevin O’Brien (2nd from right), Chairman of the Council of the Hong Kong Polytechnic University (Poly U) Dr Lam Tai-fai (4th from right) and President of Poly U Prof Teng Jin-guang (3rd from left), East Asia Regional Chairman of Arup Michael Kwok (right), Vice Chairman of Ronald Lu and Partners Bryant Lu (2nd from left) and Managing Director, Property & Buildings, China Region of WSP Colin Chung (left) take a group photo at the Caroline Hill Road pop-up Community Vaccination Centre.

Photo-4.jpg

The new pop-up Community Vaccination Centre at Caroline Hill Road is the largest yet set up within a private property portfolio, created using pre-fabricated containers. It is expected to be capable of serving several hundred thousand more citizens to get fully vaccinated during its 3-month operational period.

Constructed in an exceptionally short period of just 18 days, the CVC offers 18 vaccination booths, providing a smooth and comfortable experience for the public. Gammon Construction, which has also sponsored the initiative, took the lead in creating the temporary facilities using pre-fabricated containers, working alongside other partners including Arup, Ronald Lui and Partners and WSP. The site was handed over to the Hong Kong Government on 23 March 2022 and will be operational for three months until the end of June. The School of Nursing at the Hong Kong Polytechnic University will operate the vaccination centre in a non-profit-making mode.

“Since the start of the pandemic, we’ve assiduously explored how we can use our property spaces and other resources to help the Government and the community combat the pandemic,” explains Chinachem Group’s Executive Director and CEO Donald Choi. “As in this case, we’ve also joined hands with like-minded partners where possible to maximise the support we can offer, and help speed Hong Kong’s recovery through a team effort. This exemplifies our people-centric philosophy and our vision of creating shared value for the community through a ‘Triple Bottom Line’ approach, which balances People, Prosperity and Planet.”

Chinachem Group has also made a number of its hotels available for quarantine or isolation purposes, while Nina Hotel Tsuen Wan West recently hosted a community vaccination day co-organised with Tsuen Wan District Office. In late January, the Group organised pop-up mini-flower markets at selected properties to support local farmers affected by the last-minute cancellation of the traditional Chinese New Year markets.

Besides putting its properties to good use amid the pandemic, the Group has helped make 100,000 Rapid Antigen Test (RAT) kits available to people in need, donating 50,000 kits directly and a further 50,000 through matching donations by C-MER Eye Care Holdings and Shenzhen YHLO Biotech. The first batch of 20,000 RAT kits were delivered to the Fu Hong Society to help its residential care homes and daycare centres combat the pandemic. The remaining 80,000 were packed into 8,000 goodie bags – together with other anti-epidemic supplies and daily necessities such as masks, hand sanitiser, canned food and more – then distributed to subdivided flat households in Tsuen Wan, Sham Shui Po and Yau Tsim Mong districts, benefiting around 4,000 low-income families. To ensure the timely and safe delivery of these supplies and ease the current pressure on NGOs, the Group arranged distribution through smart logistics start-up Zeek, in which it is an investor.

The Group has also donated HK$500,000 to Hong Kong Sheng Kung Hui Welfare Council to alleviate their substantial expenses of employing temporary care workers, paying special allowances, and purchasing anti-epidemic supplies and disinfection.

In the earlier stages of the Government’s vaccination drive, the Group organised a HK$20 million Vaccination Lucky Draw to encourage more people to get vaccinated. By playing its part to boost the city’s vaccination rate, the Group hopes that Hong Kong can build a sufficient immunity barrier to speed up its relaxation of anti-epidemic measures and return to a healthy economy.

The Group will continue to provide support and care to citizens in need while paying close attention to their well-being. The Group will join hands with others in the city to fight against the epidemic and build a beautiful home together.

Chinachem Group

Since 1960, Chinachem Group has been a leading property developer in Hong Kong, with a portfolio covering residential, commercial, retail and industrial buildings for sales and investment, in addition to operating hotels and property management services. The Group actively seeks to make a positive contribution to society through its adherence to the “Triple Bottom Line”, a commitment that its activities will benefit People, bring Prosperity to the community and preserve the Planet. Please visit .

#ChinachemGroup

The issuer is solely responsible for the content of this announcement.

Creation Design & Contracting launches a one-stop school engineering service to help schools handling summer vacation projects

HONG KONG SAR – Media OutReach – 29 March 2022 – To improve learning environments, many schools strive to carry out school refurbishments during summer vacations. In addition, many schools are also preparing to build onsite STEM LABs to cooperate with the STEM education that is actively promoted by the Education Bureau in recent years. However, the “early summer vacation” caused by the raging fifth wave of the epidemic has disrupted many school refurbishments plans.

Given this, Creation Design & Contracting , with its professional team of experienced School Design, Construction, and Education experts, has launched a one-stop school refurbishment service to ensure that every part of the design is conducive to the development of a diverse learning space by improving communication.

School refurbishment design should ensure the high quality of the learning environment and the safety of students. There are many areas to pay attention to in school refurbishment, and thus an experienced construction team is required. Creation Design & Contracting has a wealth of STEM ROOM Design and Decoration experience, from materials, design, furniture customization, time management, to school refurbishment budgets, such as subsidies from the Quality Education Fund (QE Fund) or kindergarten school building decoration allowance. As these mentioned funds will be processed through strict approval and review, further details cannot be ignored.

To cope with the epidemic, Creation Design & Contracting has also assisted many schools in optimizing the ventilation conditions of the school premises, including purchasing ventilation testing services and purchasing air purifiers or carrying out other minor improvement works to meet the government’s ventilation requirements. Professional designers and refurbishment teams would commit to fulfilling the needs of each teacher and student, customizing the refurbishment planning of the learning space, and creating a unique cooperative learning space.

About Creation Design & Contracting Limited:

Creation Design & Contracting Limited is a refurbishment design company that undertakes various types of refurbishment works, minor refurbishment works, , and works. The company is sincerely committed to providing a one-stop service, providing customers with professional analysis and design solutions free of charge. Moreover, the company also provides easy-to-follow quotations. Each refurbishment project progress would be supervised, and the company would report each stage of the refurbishment progress and keep close contact with its customers.

#CreationDesign&Contracting

Storms Pummel Homes in Luang Prabang and Champasack Provinces

Storms Pummel Homes in Luang Prabang and Champasack Provinces.

Storms have damaged houses and other structures in the provinces of Luang Prabang and Champasack, following a storm warning issued by the Department of Meteorology and Hydrology.

Laos Confirms 2,183  New Cases of Covid-19

Covid-19 Update Xayaboury

Laos has recorded 2,183 cases of Covid-19 across the country today.

Borsa Vini Italiani Returns for Its 3rd Edition In November, With A Spectacular Selection Of The Finest Italian Wines

SINGAPORE – Media OutReach – 29 March 2022 – Following the success of its 2nd edition of Borsa Vini Italiani, the one-day trade exhibition will return to Singapore for its 3rd edition this November, bringing together a new selection of spectacular Italian wines that will sure to impress local wine buyers, connoisseurs and sommeliers. Borsa Vini 2022 is organised by the Italian Trade Agency (ITA). This year it will be held within the framework of the Italian Cuisine Week, a special initiative presented by the Embassy of Italy, in collaboration with ITA and other Italian institutional partners in November.

Leading up to this year’s edition, ITA will be organising various initiatives for 2022 in close coordination and collaboration with the Embassy of Italy in Singapore. On one spectrum, ITA will explore several new innovative sectors such as fintech, smartmobility, agritech, renewables energy, together with a dedicated acceleration programme for Italian startups to be hosted in Singapore. On the other, ITA will continue to promote Italy’s excellences in the traditional sectors, such as design, furniture, jewellery, luxury, food and beverage (F&B), as well as to drive awareness and appreciation for wines from the North, centre and South of Italy.

Aside from Borsa Vini 2022, ITA will be participating in the Food&HotelAsia (FHA) event on 5-8 September 2022 to showcase the best of Italian food in South East Asia. Attendees can look forward to live cooking demonstrations with Italian chefs, masterclasses, specific talks on sustainable and innovative food and the promotion of Italian products displayed throughout the event. Within the FHA exhibition, ITA will also be present with a pavilion at Prowine, an exhibition on wine which saw the participation of 270 wine makers from 33 different countries in the previous edition.

H.E Ambassador of Italy to Singapore, Mario Andrea Vattani said, “In the last few years Singaporeans enjoy more and more Italian food and wine. Our F&B exports to Singapore grew by over 15% in 2021, and they’re still going up. We’re very happy to see that it’s our wines who have been the drivers of this growth, because our wines tell us much more than the story of their distinctive taste and high quality. Our wines embody the spirit of our territory, the variety of our regions, and the roots of our millenary history. For many of our Singaporean friends, to enjoy a glass of Italian wine is to finally travel back to the Italian landscapes that they know so well. Through the Borsa Vini event we will bring together a fine selection of wineries and of Singaporean importers, with seminars by professional sommeliers to make sure that culture and taste continue to thrive in Singapore, truly one of the food Capitals of the world.”

Commenting on Borsa Vini’s returning showcase in Singapore, Ilaria Piccinni, Deputy Trade Commissioner of the Italian Trade Agency in Singapore said, “We’re excited to be back out and about again, celebrating the best in Italian wine and culture with the return of Borsa Vini’s 3rd edition in Singapore. The challenges of COVID-19 is still being felt throughout the world, but we’ve seen a leap in demand in many markets after overcoming 2020’s pandemic slump. For instance, there’s been a significant change in consumer behaviour and a growing appetite amongst consumers who are embracing mindful drinking while exploring and experimenting new tastes and diverse wine varieties. Beyond the traditional, we’ve also turned up the notch on innovation, sustainability and have leveraged our network of wine portfolios with Made in Italy excellence, to expand the presence of Italian wines in Singapore.”

Famed as the leading producer of excellent wine, Italian wines from the European country are world-renowned for their quality, tradition and innovation. Their autochthone vineyards are highly appreciated both in Italy and on international markets. The F&B sector in Italy represents a key industry with total exports topping 43 billion Euros in 2021, making up 9% of its total exports. In Asia, Italian F&B exports are enjoying a continuous double-digit growth in the last three years, interrupted only in 2020 due to economic downturn caused by the pandemic. In Singapore, they continue to be popular with exports growing by 15.1% in Jan-Nov 2021 (97.2 million Euro) compared to the same period of 2020 surpassing the exports registered in Jan-Nov 2018 and 2019. As of the same period, Italy retained its long-standing 2nd position among EU countries as a Singapore supplier of wine, behind France, and 5th position worldwide behind France, Australia, UK, and China.

More details about Borsa Vini 2022 and the full list of participating wine companies will be announced later this year. For more information, visit https://www.ice.it/en/.

About Italian Trade Agency

The Italian Trade Agency (ITA) is the governmental agency that supports the development of their companies abroad and promotes the attraction of foreign investment in Italy. With a motivated and modern organization and a widespread network of overseas offices, ITA provides information, assistance, consulting, promotion and training to Italian small and medium-sized businesses. Using the most modern multi-channel promotion and communication tools, it acts to assert the excellence of Made in Italy in the world. ITA offices are the ideal gateway for enterprises to establish business relationships with Italian partners, from sourcing Italian products, to investment opportunities in Italy. For more information, visit .

#ItalianTradeAgency

The issuer is solely responsible for the content of this announcement.

Laos-China Railway Suspends Vientiane-Luang Prabang Route Amid Omicron Outbreak

Laos-China Railway suspends services amid Omicron outbreak

The Laos-China Railway has suspended some passenger train operations between Vientiane and Luang Prabang until 31 March.

SSY Group Limited announces 2021 annual results

Net profits up 28% to HK$786 million with final dividend HK$0.07/share

Promote scientific research innovation; Optimisation of product mix

Results summary:

  • Total revenue HK$5,357 million, representing an increase of 25.7% y-o-y
  • Net profits HK$786 million, representing an increase of 28.4% y-o-y
  • The Board resolved to pay final dividend of HK$0.07 /share

HONG KONG SAR – Media OutReach – 29 March 2022 – SSY Group Limited (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the annual results of the Company for the year ended 31 December 2021 (“2021” or “the year”).

During the year, the Group achieved a revenue of HK$5,357 million, representing an increase of 25.7% and the gross profit margin decreased by 4.4 percentage point to 59.2%. The Group achieved net profits of HK$786 million, representing an increase of 28.4% compared with last year. Faced with the adjustments in the pharmaceutical market and industrial policy amidst the normality under novel coronavirus epidemic, the Group made concerted efforts to overcome the various adverse effects brought by the epidemic and market competition with its endeavor in operation and implementation of various measures to ensure market support. As the Group made strenuous efforts to promote scientific research, innovation and structural optimisation, new products and product types under evaluations have been approved successively. With the accelerated utilisation of the production capacity of main bulk pharmaceuticals and preparations, the Group delivered favourable performance in promoting the integrated development in relation to the whole industry chain and diversified forms from medical materials, bulk pharmaceuticals to high value-added preparations, providing sufficient momentum for the future development of the Group. The Group increased its effort in promoting market development for conventional preparations and main preparations. At the same time, in light of changes in demands from the industrial chain, the Group stepped up efforts in increasing the production and sales of its major bulk pharmaceuticals and medical materials, so as to ensure a continuously and consistently favourable operation performance overall. Taking the opportunity brought by National Centralised Medicines Procurement as well as provincial and regional Group Purchasing Organisation Programme, the Group continuously expanded the market accessibility of its products.

The Board of directors resolved to pay a final dividend of HK$0.07 per share for year 2021, together with interim dividend HK$0.05 per share, total dividend for full year of 2021 will be HK$0.12 per share, representing an increase of 20% from last year.

Amidst the normality under epidemic, the domestic pharmaceutical market restored a stable supply and demand condition. The Group continued to increase its market shares and remained its leading position in the infusion market. In 2021, the sales volume of infusion solutions reached approximately 1,358 million bottles (bags), representing an increase of approximately 13.8% compared to last year. The revenue of infusion solutions reached approximately HK$3,304 million, representing an increase of 25.3% compared to last year. Ampoule product line has become a powerful boost and new growth driver for the Group’s injection segment as it has become increasingly rich in varieties with its production and sales gradually scaled up. During the year, the revenue of ampoule products was approximately HK$1,094 million, representing an increase of approximately 12.6% as compared to last year, which continued to maintain a good growth momentum. In respect of bulk pharmaceuticals business, the Group achieved continuous improvement in sales revenue and substantial increase in sales volume of main products. A number of types of products were granted production approvals, and the product mix has become increasingly diversified. The revenue from bulk pharmaceuticals reached HK$534 million, representing an increase of 131.9% as compared to last year. Solid preparations business segment recorded a steady increase in production and sales. Leveraging on tender awarded for National Centralised Medicines Procurement of Cefdinir capsule and Prucalopride Succinate tablet, further improve the product accessibility and brand penetration and the market influence expanded to the whole of China. In respect of medical materials, Jiangsu Best New Medical Material stepped up efforts to strengthen the product upgrade and technology advancement of major products, and enhanced the supporting ability of the leading products for production in downstream production chains, which facilitated the enhancement of its production capacity and market coverage. Newly developed multi-layer co-extrusion bioprocessing films for single-use system in liquid dosing has been put into industrial production and resulted in sales, which is used to replace those imported bioprocessing films and has broad market development prospects.

Upholding the innovation-driven strategy, with the positive result from innovation achievements, the Group’s product portfolio was increasingly enriched and improved. Type 1 new drug NP-01, the first innovative drug type of the Group, has entered into the research of Phase I clinical trial. The Group has stepped up efforts to push forward the preliminary research on anti-liver fibrosis Type 1 innovative drug ADN-9, anti-epileptic compound QO-83, self-developed anti-pulmonary hypertension Type 1 innovative drug and anti-tumor Type 2 chemical innovative drug Miriplatin. During the year, 63 projects were applied for national production approval by the Group, including 39 new types of liquid and solid preparations and 13 bulk pharmaceuticals. During the year, a total of 20 national production approvals were obtained and 7 product specifications have passed the consistency evaluations. From January to March of 2022, there are another 5 products which passed the consistency evaluation. Currently, 20 types with 28 product specifications of the Group have passed consistency evaluation or have been regarded as passing the consistency evaluation, which played a stronger facilitation and stimulation role in consolidating and expanding market shares. The construction project of bioprocessing film of Jiangsu Best began as scheduled.

The new product, 7-layer bioprocessing barrier films of 1.6 metres width, has been put into trial production by the end of 2021, and samples were provided to customers for testing. Together with the second production line for 7-layer bioprocessing barrier films which is targeted to commence trial production in June 2022, the annual production capacity of bioprocessing films will increase by 20 million square metres, thus enhancing the Group’s ability in market supply. Application for listing on the National Equities Exchange and Quotations in respect of the medical materials segment has been accepted, and follow-up works are in progress orderly. In addition, in light of the current development of the industry, the Group completed the acquisition of 6.1% of the equity interest in Cisen Pharmaceutical in a timely manner in 2021, which is expected to bring long-term return and new development opportunity for the Group. The Group has acquired as a vertical integration of the whole of the equity interest in Cangzhou Lingang Youyi Chemical in March 2022. The completion of the acquisition provided important supports and guarantees for the enhancement of stable supply for the caffeine production chain, optimisation of production costs and achievement of the goal of an annual production of 7,000 tonnes of caffeine.

Looking ahead in 2022, the economic situation will remain complicated and dynamic amidst the normality under global pandemic. Facing the combined pressure arising from external factors that may persist and bring new challenges to the Group’s production and operation, the Group will push forward the supply-side structural reform and strive to achieve more solid operating results. By focusing on its core injection business of injections, the Group will further develop its existing market and make continuous effort to explore new markets, with an aim to establish a new development landscape. The Group will make an in-depth and better systematic analysis on the national and local centralised procurement policies. Capitalizing on the radiation and driving effects of the Group Purchasing Organisation Programme, the Group will strive to expand the proportion of high value-added products in terms of production and sales volume, maintain its leading position in the market. In addition, the Group will proactively push forward the industrialisation and marketisation of the solid preparation products that were recently approved and aim to expand and strengthen its solid preparation segment. At the same time, the Group will push forward the promotion and usage of bioprocessing films in China, strive to strengthen its industry position and product influence in the field of medical materials. On the other hand, with the goal of reducing costs and improving capacity utilization, we will actively cultivate and expand the bulk pharmaceuticals business. The Group will proactively construct and develop an innovative high-energy ecosystem, explore the advantages of convergence of technology, talents and capital to continuously improve the levels and grades of innovation development. Adhering to the strategy of “combination of generic and innovative drugs”, the Group will make concerted effort to enhance the efficiency in the research and development of its advantageous products in generic drugs, innovative drugs, bulk pharmaceuticals and medical materials, accumulating strength for the sustainable development of the Group. The Group will continue to proactively push forward the spin-off listing of its medical materials segment and bulk pharmaceuticals segment on the domestic market. At the same time, the Group will actively seek opportunities of merger and acquisition as well as investment in the pharmaceutical industry.

Mr. Qu Jiguang, Chairman and CEO of SSY Group Limited said, “Facing the persistent risks and challenges in the post-pandemic era, the pharmaceutical industry will be confronted with the greatest changes in this century. Self-developed innovation driven by market demand, the integration and collaboration based on controllable supply chain, and the enhanced efficiency brought by the trend of digital transformation will become the important drivers for the progress and breakthroughs of the overall industry and the Group. While accelerating the optimisation of industrial structure, improvement of sales of product and construction progress of infrastructure projects, the Group will expedite the progress of spin-off listing of the medical materials segment and bulk pharmaceuticals segment, and strive for a win-win situation in the product and capital market. By virtue of the scale, quality, management and brand advantages accumulated in the industry over the years and the continuous innovation momentum released by the Group, we firmly believe that we will be able to create new high record in terms of production output, sales and profit in 2022, and bring satisfactory returns to our investors with a stronger result of development.”

About SSY Group Limited

SSY Group Limited is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005. The Group is principally engaged in the research, development, manufacture and sale of a wide range of pharmaceutical products, including OTC drugs, bulk medicine and medical materials, mainly intravenous infusion solution and ampoule injection to hospital and distributors. The manufacturing plants of the Group locates in Hebei Province and Jiangsu Province in China, its products take leading position in the high-end hospital market in China.

#SSYGroup

The issuer is solely responsible for the content of this announcement.